(239 days)
The iPlan Hip Templating system is indicated for the preoperative planning of orthopedic treatments. It is specially developed for the preparation and display of anatomical patient data that has been acquired using xray, CT or MR equipment.
iPlan Hip Templating creates treatment plans in conjunction with 2D / 3D implant models are provided by a separate database. Both 2D and 3D planning are supported, depending on the anatomical information available.
The treatment plan can either be saved or printed as required.
iPlan Hip Templating is a stand-alone system for preoperative orthopedic treatment planning which facilitates digital template planning for anatomical images. Once image scaling has been completed, using an object of known size that is positioned next to the anatomical area of interest during image acquisition, the surgeons can use a range of measurement tools in order to select the optimum implant for the patient. The software overlays 2D / 3D implant models onto the image data and displays the result. The measurement tools can also be used to display preplanned and current values where required.
The digital implant models are provided by a separate implant database. Both 2D implant contours and 3D implant models are available.
Treatment plans can be saved and printed out as required. The information stored in the treatment plan can be loaded to other BrainLAB applications and used to support image guided surgery in a VectorVision system, for example.
Here's an analysis of the provided text regarding the iPlan® Hip Templating device, focusing on acceptance criteria and the study proving its performance:
1. Table of Acceptance Criteria and Reported Device Performance
The provided document does not explicitly state specific acceptance criteria (e.g., target accuracy percentages, precision thresholds) or detailed reported device performance in a quantitative manner.
Instead, the document makes a general statement:
| Acceptance Criteria | Reported Device Performance |
|---|---|
| Safety and effectiveness of the system | "The validation proves the safety and effectiveness of the system." |
2. Sample Size Used for the Test Set and Data Provenance
The document does not provide any specific information regarding:
- The sample size used for any test set.
- The country of origin of the data.
- Whether the data was retrospective or prospective.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications
The document does not provide any information regarding:
- The number of experts used to establish ground truth.
- The qualifications of those experts.
4. Adjudication Method for the Test Set
The document does not mention any adjudication method used for a test set.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
The document does not mention or describe a multi-reader multi-case (MRMC) comparative effectiveness study. Therefore, no effect size of human improvement with AI vs. without AI assistance can be determined from this text.
6. Standalone (Algorithm Only) Performance Study
The document mentions that "iPlan Hip Templating is a stand-alone system for preoperative orthopedic treatment planning," implying its intended use as an algorithm-only tool for planning. However, it does not describe a specific standalone performance study in terms of metrics. The phrase "The validation proves the safety and effectiveness of the system" is a general statement about the system as a whole, not a detailed report of standalone algorithmic performance.
7. Type of Ground Truth Used
The document does not specify the type of ground truth used for any validation or testing.
8. Sample Size for the Training Set
The document does not provide any information regarding the sample size for the training set.
9. How the Ground Truth for the Training Set Was Established
The document does not provide any information regarding how the ground truth for the training set was established.
Summary of Findings:
The provided document (K042543 510(k) Summary) is a high-level regulatory submission focusing on demonstrating substantial equivalence to a predicate device (iPlan!®2 K020631). It asserts that the validation process (per BrainLAB's procedures) proves the safety and effectiveness of the system. However, it lacks the detailed technical information and study results typically found in reports specifically designed to describe acceptance criteria and evidence of meeting them. This type of information is often contained in the full 510(k) submission, which is not fully provided here. The summary focuses on the intended use, device description, and the FDA's concurrence with substantial equivalence rather than granular performance metrics and study details.
{0}------------------------------------------------
MAY 1 7 2005
KO4 2543 510 (k) Summary of Safety and Effectiveness for iPlan® Hip Templating
Manufacturer:
| Address: | BrainLAB AG |
|---|---|
| Ammerthalstrasse 8 | |
| 85551 Heimstetten | |
| Germany | |
| Phone: +49 89 99 15 68 0 | |
| Fax: +49 89 99 15 68 33 | |
| Contact Person: | Mr. Rainer Birkenbach |
| Summary Date: | February 2, 2005 |
| Device Name: | |
| Trade name: | iPlan® Hip Template |
Irade name:
Common/Classification Name:
iPlan® Hip Templating Planning System
Predicate Device: iPlan!®2 (K020631)
Device Classification Name: Stereotaxic instrument Requlatory Class: Class II
Intended Use:
The iPlan Hip Templating system is indicated for the preoperative planning of orthopedic treatments. It is specially developed for the preparation and display of anatomical patient data that has been acquired using xray, CT or MR equipment.
iPlan Hip Templating creates treatment plans in conjunction with 2D / 3D implant models are provided by a separate database. Both 2D and 3D planning are supported, depending on the anatomical information available.
The treatment plan can either be saved or printed as required.
Device Description:
iPlan Hip Templating is a stand-alone system for preoperative orthopedic treatment planning which facilitates digital template planning for anatomical images. Once image scaling has been completed, using an object of known size that is positioned next to the anatomical area of interest during image acquisition, the surgeons can use a range of measurement tools in order to select the optimum implant for the patient. The software overlays 2D / 3D implant models onto the image data and displays the result. The measurement tools can also be used to display preplanned and current values where required.
The digital implant models are provided by a separate implant database. Both 2D implant contours and 3D implant models are available.
{1}------------------------------------------------
Treatment plans can be saved and printed out as required. The information stored in the treatment plan can be loaded to other BrainLAB applications and used to support image guided surgery in a VectorVision system, for example.
Substantial equivalence:
iPlan® Hip Templating has been verified and validated according to BrainLAB's procedures for product design and development. The validation proves the safety and effectiveness of the system. The information provided by BrainLAB in this 510 (k) application was found to be substantially equivalent with the predicate device iPlan® (K020631).
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image is a seal for the Department of Health & Human Services - USA. The seal is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the seal is a stylized image of a bird or eagle with its wings spread.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
MAY 1 7 2005
Mr. Oliver Fleig Project Manager BrainLAB AG Ammerthalstraße 8 85551 Heimstetten, Germany
Re: K042543
Trade/Device Name: iPlan Hip Templating Regulation Number: 21 CFR 882.4560 Regulation Name: Stereotaxic instrument Regulatory Class: II Product Code: HAW Dated: April 12, 2005 Received: April 19, 2005
Dear Mr. Fleig:
We have reviewed your Section 510(k) premarket notification of intent to market the device indicati We have reviewed your Section 910(x) premained issubstantially equivalent (for the indications ferenced above and nave decemined by marketed predicate devices marketed in interstate for use stated in the encrosule) to regally manation posice Americal Device Ameral Food. For a commerce prior to May 26, 1776, the enaomine with the provisions of the Federal Food, Drug, devices that have been recuire approval of a premarket approval application (PMA).
and Cosmetic Act (Act) that do not require approval of a premarket approval or a of the Act and Cosment Act (Act) that to not require approvile of the general controls provisions of the Act. The You may, merelore, market the dovices, sayes to use include registration, listing of general controls provisions of the free labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), If your device is Classifica (Sec above) into v. Existing major regulations affecting your device . EDA it may be subject to such additional conferent in 21, Parts 800 to 898. In addition, FDA can be found in the Code of Feceral concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean Please be advised that I DA s Issualites of a succession in ther requirements of the Act
that FDA has made a determination that your device complies with other mat that FDA has made a decemination administered by other Federal agencies. You must or any Federal statures and regulations daministered of registration and listing (21 comply with all the Act STEquirements, moradian and manufacturing practice requirements as setting CFR Part 807), labeling (21 CFR Part 820), and if applicable, the electronic forul in the quality systems (Sections 531-542 of the Act); 21 CFR 1000-1050.
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{3}------------------------------------------------
Page 2 – Mr. Oliver Fleig
This letter will allow you to begin marketing your device as described in your Section 5 10(k) I his letter will anow you to begin mankomig your as receive of your device to a legally premarket nouthcation. "The PDF Imaning of Essional for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please If you desire specific advice for your don't a most and mease note the regulation entitled, and Colliact the Office of Complance at (21 t r = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = " Misofanding by relectice to premailied.com in the Act from the Division of Small other general Information on your respensentation of its toll-free number (800) 638-2041 or Manufacturers, International and Consultip://www.fda.gov/cdrl/industry/support/index.html.
Sincerely yours,
Edin S. Ramic
-Miriam C. Provost, Ph.D. Acting Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
510(k) Number (if known): K 042543
Device Name:
iPlan Hip Templating
The iPlan Hip Templating system is indicated for the preoperative planning of orthopedic The iPlan Hip Templainig System is indicated for the properiation and display of anatomical patient data that has been acquired using x-ray, CT or MR equipment.
that has boon with the same in conjunction with 2D / 3D implant models.
iPlan Hip Templating creates treatment plans in clarge and 3D planning are supposition iPlan Hip Templating Creates ucatinent productions of the 2D and 3D planning are supported, miplain models anatomical information available.
..............................................................................................................................................................................
The treatment plan can either be saved or printed as required.
X Prescription Use __ (Per 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Signature
General, Restorative
Logical Devices
§ 882.4560 Stereotaxic instrument.
(a)
Identification. A stereotaxic instrument is a device consisting of a rigid frame with a calibrated guide mechanism for precisely positioning probes or other devices within a patient's brain, spinal cord, or other part of the nervous system.(b)
Classification. Class II (performance standards).